Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19
PharmD, BCPS, BCIDP Erin K Mccreary, J Ryan Bariola, MD Richard J Wadas, Judith A Shovel, Mary Kay Wisniewski, Michelle Adam, BS Debbie Albin, MS Tami Minnier, MD Mark Schmidhofer, MBA Russell Meyers, MD Oscar C Marroquin, MBA Kevin Collins, PhD William Garrard, Lindsay R Berry, PhD Scott Berry, PhD Amy M Crawford, PhD Anna Mcglothlin, MS Kelsey Linstrum, MS Anna Nakayama, MS Stephanie K Montgomery, MD Graham M Snyder, MD Donald M Yealy, MD MPH Derek C Angus, PhD Paula L Kip, MD MSc Christopher W Seymour, MD MPH David T Huang, PhD Kevin E Kip
doi:10.1101/2021.11.30.21266756
Findings: Among 1,956 propensity-matched adults, outpatients who received casirivimab and imdevimab subcutaneously had a 28-day rate of hospitalization or death of 3.4% (n=652) compared to 7.8% (n=1,304) in non-treated controls [risk ratio 0.44 (95% confidence interval: 0.28 to 0.68, p < .001)]. Among 2,185 outpatients who received subcutaneous (n=969) or intravenous (n=1,216) casirivimab and imdevimab, the 28-day rate of hospitalization/death was 2.8% vs. 1.7%, respectively, which resulted in an adjusted risk difference of 1.5% (95% confidence interval: -0.5% to 3.5%, p=.14). The 28-day adjusted risk differences comparing subcutaneous to intravenous route for death, ICU admission, and mechanical ventilation were 0.3% or less, although the 95% confidence intervals were wide. Meaning: Subcutaneously administered casirivimab and imdevimab is associated with reduced hospitalization or death amongst outpatients with mild to moderate COVID-19 compared to no treatment, and has a small, adjusted risk difference compared to patients treated intravenously.
Treated and Nontreated Analysis
References
Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res,
doi:10.1080/00273171.2011.568786Bariola, Mccreary, Wadas, Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection, Open Forum Infect Dis,
doi:10.1093/ofid/ofab254Benchimol, Sl, Guttmann, Harron, The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement, PLoS Med
Gov, Uk, Patient information leaflet for Ronapreve
Huang, Mccreary, Bariola, The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization, Trials,
doi:10.1186/s13063-021-05316-3O'brien, Forleo-Neto, Musser, Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2109682Pfizer, A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19
Reitz, Seymour, Vates, Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients, BMJ Open,
doi:10.1136/bmjopen-2020-037690Rosenbaum, Rubin, The Central Role of the Propensity Score in Observational Studies for Causal Effects, Biometrika,
doi:10.2307/2335942Sharp, Corporation, Efficacy and safety of molnupiravir (MK-4482) in nonhospitalized adult participants with COVID-19
DOI record:
{
"DOI": "10.1101/2021.11.30.21266756",
"URL": "http://dx.doi.org/10.1101/2021.11.30.21266756",
"abstract": "<jats:p>Importance: Monoclonal antibody (mAb) treatment decreases hospitalization and death in outpatients with mild to moderate COVID 19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous administration may expand outpatient treatment capacity and qualified staff available to administer treatment, but association with patient outcomes is understudied. \nObjective: To evaluate whether or not, i.) subcutaneous casirivimab and imdevimab treatment is associated with reduced 28 days hospitalization/death than non-treatment among mAb-eligible patients, and ii.) subcutaneous casirivimab and imdevimab treatment is clinically and statistically similar to intravenous casirivimab and imdevimab treatment.\nDesign, Setting, and Participants: Prospective cohort study of outpatients in a learning health system in the United States with mild to moderate COVID 19 symptoms from July 14 to October 26, 2021 who were eligible for mAb treatment under emergency use authorization. A nontreated control group of eligible patients was also selected.\nIntervention: Subcutaneous injection or intravenous administration of the combined single dose of casirivimab 600mg and imdevimab 600mg.\nMain Outcomes and Measures: The primary outcome was the 28 day adjusted risk ratio or adjusted risk difference for hospitalization or death. Secondary outcomes included 28 day adjusted risk ratios/differences of hospitalization, death, composite endpoint of ED admission and hospitalization, and rates of adverse events.\nResults: Among 1,956 matched adults with mild to moderate COVID 19, patients who received casirivimab and imdevimab subcutaneously had a 28-day rate of hospitalization/death of 3.4% (n=652) compared to 7.8% (n=1,304) in nontreated controls [risk ratio 0.44 (95% confidence interval: 0.28 to 0.68, p < .001)]. Among 2,185 patients treated with subcutaneous (n=969) or intravenous (n=1,216) casirivimab and imdevimab, the 28 day rate of hospitalization/death was 2.8% vs. 1.7%, respectively which resulted in an adjusted risk difference of 1.5% (95% confidence interval: -0.5% to 3.5%, p=.14). The 28 day adjusted risk differences (subcutaneous and intravenous) for death, ICU admission, and mechanical ventilation were 0.3% or less, although the 95% confidence intervals were wide. \nConclusions and Relevance: Subcutaneously administered casirivimab and imdevimab is associated with reduced risk adjusted hospitalization or death amongst outpatients with mild to moderate COVID 19 compared to no treatment and indicates low adjusted risk difference compared to patients treated intravenously.</jats:p>",
"accepted": {
"date-parts": [
[
2021,
12,
1
]
]
},
"author": [
{
"affiliation": [],
"family": "McCreary",
"given": "Erin K.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Bariola",
"given": "J. Ryan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wadas",
"given": "Richard J.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Shovel",
"given": "Judith A.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wisniewski",
"given": "Mary K.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Adam",
"given": "Michelle",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Albin",
"given": "Debbie",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Minnier",
"given": "Tami E.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Schmidhofer",
"given": "Mark",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Meyers",
"given": "Russell",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Marroquin",
"given": "Oscar C.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Collins",
"given": "Kevin",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Garrard",
"given": "William",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Berrry",
"given": "Lindsay R.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Berry",
"given": "Scott",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Crawford",
"given": "Amy M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "McGlothlin",
"given": "Anna",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Linstrum",
"given": "Kelsey",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Nakayama",
"given": "Anna",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Montgomery",
"given": "Stephanie K.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Snyder",
"given": "Graham M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yealy",
"given": "Donald M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Angus",
"given": "Derek C.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kip",
"given": "Paula L.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Seymour",
"given": "Christopher W.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Huang",
"given": "David T.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kip",
"given": "Kevin E.",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T23:25:15Z",
"timestamp": 1638401115000
},
"deposited": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T23:25:15Z",
"timestamp": 1638401115000
},
"group-title": "Infectious Diseases (except HIV/AIDS)",
"indexed": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T23:50:08Z",
"timestamp": 1638402608075
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2021,
12,
1
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2021.11.30.21266756",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2021,
12,
1
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2021,
12,
1
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference-count": 0,
"references-count": 0,
"relation": {},
"score": 1,
"short-container-title": [],
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": [
"Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19."
],
"type": "posted-content"
}
